Development and validation of immunoassays to quantify the half-antibody exchange of an IgG4 antibody, natalizumab (Tysabri®) with endogenous IgG4-Reference-Cited by-同舟云学术

Development and validation of immunoassays to quantify the half-antibody exchange of an IgG4 antibody, natalizumab (Tysabri®) with endogenous IgG4

Published:2011-04 Issue:1 Volume:55 Page:168-175
ISSN:0731-7085
Container-title:Journal of Pharmaceutical and Biomedical Analysis
language:en
Short-container-title:Journal of Pharmaceutical and Biomedical Analysis

Author:

Shapiro Renée I.,Plavina Tatiana,Schlain Brian R.,Pepinsky R. Blake,Garber Ellen A.,Jarpe Matthew,Hochman Paula S.,Wehner Nancy G.,Bard Frederique,Motter Ruth,Yednock Ted A.,Taylor Frederick R.

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Analytical Chemistry

Reference13 articles.

1. IgG effector mechanisms;Clark;Chem. Immunol.,1997

2. IgG4 breaking the rules;Aalberse;Immunology,2002

3. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo;Labrijn;Nat. Biotechnol.,2009

4. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange;van der Neut Kolfschoten;Science,2007

5. Intrachain disulfide bond in the core hinge region of human IgG4;Bloom;Protein Sci.,1997

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial;Expert Opinion on Biological Therapy;2023-12-02

2. High levels of endothelial ICAM-1 prohibit natalizumab mediated abrogation of CD4+ T cell arrest on the inflamed BBB under flow in vitro;Journal of Neuroinflammation;2023-05-23

3. Peptide Mimotope-Enabled Quantification of Natalizumab Arm Exchange During Multiple Sclerosis Treatment;Therapeutic Drug Monitoring;2023-02

4. Factors affecting IgG4-mediated complement activation;Frontiers in Immunology;2023-01-26

5. Integrin-directed antibody-based immunotherapy: focus on VLA-4;Immunotherapy Advances;2021-01-01